<DOC>
	<DOC>NCT00603291</DOC>
	<brief_summary>The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.</brief_summary>
	<brief_title>BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Overweight/obese men and women with type 2 diabetes mellitus that is managed with oral antihyperglycemic agent(s). Body mass index (BMI) 27 to 45 kg/m2, inclusive. Ability to complete a 1 year study Pregnancy Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months prior to screening History of symptomatic heart valve disease Serious or unstable current or past medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOOM-DM</keyword>
	<keyword>hypertension</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>